Thermo Fisher Scientific Completes Acquisition of Life Technologies
Thermo Fisher Scientific (California, USA) has completed its acquisition of Life Technologies Corporation for $13.6 billion, following receipt of all required regulatory approval. Thermo Fisher has now established a new segment, Life Science Solutions that will be headed by Mark Stevenson, who served as CEO of Life Technologies.
Thermo Fisher Scientific (California, USA) has completed its acquisition of Life Technologies Corporation for $13.6 billion, following receipt of all required regulatory approval. Thermo Fisher has now established a new segment, Life Science Solutions that will be headed by Mark Stevenson, who served as CEO of Life Technologies.
The completion of the acquisition follows an earlier announced sale of Thermo Fisher’s cell culture, gene modulation, and magnetic beads business to GE Healthcare for $1.06 billion. As of 1 January 2014, the company’s financial performance will be reported in four segments:
• The new Life Sciences Solutions Segment will consist of the majority of the former Life Technologies and Thermo Fisher Biosciences businesses.
• Thermo Fisher’s Global Chemicals business will move from the Biosciences business to the Laboratory Products and Services Segment.
• Thermo Fisher’s Analytical Technologies Segment will be renamed Analytical Instruments to reflect the transfer of the Biosciences businesses to other segments, as mentioned above.
• Two small specialty diagnostics businesses within Life Technologies will become part of the Specialty Diagnostics Segment.
Marc N. Casper, President and CEO of Thermo Fisher Scientific, said: “We are pleased to announce that this transaction is now complete, and excited about our opportunity to create unrivalled leadership in serving research, life sciences, specialty diagnostics and applied markets.” He added: “Our combined offering provides cutting-edge technologies, such as genomics and proteomics, to accelerate life sciences research and improve human health. And our complementary strengths in biosciences and bioprocessing will accelerate drug discovery, development, and production. With the addition of Life Technologies, we are in an even stronger position to help our customers achieve their goals for innovation and productivity.”
For more information visit: www.thermofisher.com
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
